Human Research Protection Program

Plan

Revised December 6, 2021
Table of Contents
Scope .......................................................................................................................... 4
Purpose ....................................................................................................................... 4
Definitions .................................................................................................................. 4
Agent ............................................................................................................................ 4
Clinical Trial .............................................................................................................. 4
Engaged in Human Research ................................................................................... 4
Human Research: ...................................................................................................... 5
Human Subject as Defined by DHHS ....................................................................... 5
Human Subject as Defined by FDA ......................................................................... 5
Investigator ............................................................................................................... 5
Research as Defined by DHHS .................................................................................. 6
Research as Defined by FDA .................................................................................... 6
Mission ....................................................................................................................... 7
Ethical Requirements ............................................................................................... 7
Legal Requirements .................................................................................................. 7
Other Requirements ................................................................................................. 8
Sponsored Human Research ................................................................................... 9
Scope of Human Research Protection Program ...................................................... 9
Human Research Protection Program Policies and Procedures ............................... 10
Human Research Protection Program Components .............................................. 10
Institutional Official/Organizational Official (IO/OO) ............................................. 10
All members of the Institution ............................................................................... 11
IRBs ............................................................................................................................ 11
Investigators and Research Staff ............................................................................ 13
Legal Counsel ........................................................................................................... 13
Division Heads/Department Chairs ....................................................................... 14
Research Compliance Program ............................................................................. 14
Scientific Review Committee (SRC) ....................................................................... 14
Data Safety Monitoring (DSM) ................................................................................ 14
Institutional Conflict of Interest Committee (ICOI Committee) ............................... 15
Conflict of Interest Committee (COIC) ................................................................... 15
Environmental Health and Safety (EH&S) .............................................................. 15
Radiation Safety Committee (RSC) ....................................................................... 15
Internal Audit ........................................................................................................... 15
Office of Sponsored Programs (OSP) ...................................................................... 16
Department of Investigational Pharmacy Services (IPS) ........................................ 16
The Quality Improvement Assessment Board (QIAB) .............................................. 16
Education and Training ........................................................................................... 16
Questions and Additional Information for the IRB ................................................ 16
Reporting and Management of Concerns ............................................................... 17
Monitoring and Auditing ......................................................................................... 17
Disciplinary Actions ................................................................................................. 17
Approval and Revisions to the Plan ................................................................. 17
**Scope**
Throughout this document “Institution” refers to The University of Texas M. D. Anderson Cancer Center.

**Purpose**
This Institution is committed to protecting the rights and welfare of subjects in Human Research. The purpose of this plan is to describe this Institution’s plan to comply with ethical and legal requirements for the conduct and oversight of Human Research.

This Institution’s Human Research Protection Program is a comprehensive system to ensure the protection of the rights and welfare of subjects in Human Research. The Human Research Protection Program is based on all individuals in this Institution along with key individuals and committees fulfilling their roles and responsibilities described in this plan.

**Definitions**

**Agent**
An individual performing institutionally designated activities or exercising institutionally delegated authority or responsibility, including students, faculty, staff, employees, trainees, or visiting scholars or faculty, is considered an agent of this Institution for purposes of engagement in Human Research when that individual is on-duty in any capacity as an agent of this Institution.

Legal counsel has the ultimate authority to determine whether someone is acting as an agent of this Institution.

**Clinical Trial**
A research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.

**Engaged in Human Research**
In general, this Institution is considered engaged in federally funded Human Research when this Institution’s employees or agents for the purposes of the Human Research obtain: (1) data about the subjects of the research through intervention or interaction with them; (2) identifiable private information about or identifiable biospecimens from the subjects of the research; or (3) the informed consent of human subjects for the research. This Institution follows OHRP guidance on “Engagement of Institutions in Research”1 to apply this definition and exceptions to this definition.

---

1 [http://www.hhs.gov/ohrp/policy/engage08.html](http://www.hhs.gov/ohrp/policy/engage08.html)
Human Research:
Any activity that either:

- Is “Research” as defined by DHHS and involves “Human Subjects” as defined by DHHS (“DHHS Human Research”); or
- Is “Research” as defined by FDA and involves “Human Subjects” as defined by FDA (“FDA Human Research”).

Human Subject as Defined by DHHS
A living individual about whom an investigator (whether professional or student) conducting research (1) obtains information or biospecimens through Intervention or Interaction with the individual, and uses studies, or analyzes the information or biospecimens, or (2) obtains, uses, studies, analyzes, or generates identifiable private information or identifiable biospecimens. For the purpose of this definition:

- **Intervention** means both physical procedures by which information or biospecimens are gathered (for example, venipuncture) and manipulations of the subject or the subject’s environment that are performed for research purposes.
- **Interaction** means communication or interpersonal contact between investigator and subject.
- **Private Information** means information about behavior that occurs in a context in which an individual can reasonably expect that no observation or recording is taking place, and information which has been provided for specific purposes by an individual and that the individual can reasonably expect will not be made public (for example, a medical record).
- **Identifiable Private Information** means private information for which the identity of the subject is or may readily be ascertained by the investigator or associated with the information.
- **Identifiable Biospecimen** means a biospecimen for which the identity of the subject is or may readily be ascertained by the investigator or associated with the biospecimen.

Human Subject as Defined by FDA
An individual who is or becomes a subject in research, either as a recipient of the test article or as a control. A subject may be either a healthy human or a patient. A human subject includes an individual on whose specimen (identified or unidentified) a medical device is used.

Investigator
The person responsible for the conduct of the Human Research at one or more sites. If the Human Research is conducted by a team of individuals at a trial site, the investigator is the responsible leader of the team and may be called the principal investigator.
Research as Defined by DHHS

A systematic investigation, including research development, testing and evaluation, designed to develop or contribute to generalizable knowledge.\(^2\)

The following activities are not considered Research as Defined by DHHS:

- Scholarly and journalistic activities (e.g., oral history, journalism, biography, literary criticism, legal research, and historical scholarship), including the collection and use of information, that focus directly on the specific individuals about whom the information is collected.
- Public health surveillance activities conducted by a public health authority, limited to those necessary to allow a public health authority to identify, monitor, assess, or investigate potential public health signals, onsets of disease outbreaks, or conditions of public health importance.
  - Including the collection and testing of information or biospecimens, conducted, supported, requested, ordered, required, or authorized by a public health authority.
  - Including trends, signals, risk factors, patterns in diseases, or increases in injuries from using consumer products.
  - Including those associated with providing timely situational awareness and priority setting during the course of an event or crisis that threatens public health (including natural or man-made disasters).
- Collection and analysis of information, biospecimens, or records by or for a criminal justice agency for activities authorized by law or court order solely for criminal justice or criminal investigative purposes.
- Authorized operational activities (as determined by the relevant federal agency) in support of intelligence, homeland security, defense, or other national security missions.
- Secondary research involving non-identifiable newborn screening blood spots.

Research as Defined by FDA

Any experiment that involves a test article and one or more human subjects, and that meets any one of the following:

- Must meet the requirements for prior submission to the Food and Drug Administration under section 505(i) of the Federal Food, Drug, and Cosmetic Act meaning any use of a drug other than the use of an approved drug in the course of medical practice;

\(^2\) For research conducted within the Bureau of Prisons: Implementation of Bureau programmatic or operational initiatives made through pilot projects is not considered to be research.
• Must meet the requirements for prior submission to the Food and Drug Administration under section 520(g) of the Federal Food, Drug, and Cosmetic Act meaning any activity that evaluates the safety or effectiveness of a device; OR
• Any activity the results of which are intended to be later submitted to, or held for inspection by, the Food and Drug Administration as part of an application for a research or marketing permit.

**Mission**

The mission of this Institution’s Human Research protection program plan is to protect the rights and welfare of subjects involved in Human Research that is overseen by this Institution.

**Ethical Requirements**

In the oversight of all Human Research, this Institution (including its investigators, research staff, students involved with the conduct of Human Research, the Institution’s institutional review boards (IRBs), IRB members and chairs, IRB staff, the Institutional Official/Organization Official (IO/OO), and employees) follows the ethical principles outlined in the April 18, 1979 report of The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research titled “Ethical Principles and Guidelines for the Protection of Human Subjects of Research,” also known as “The Belmont Report”:

- Respect for Persons
- Beneficence
- Justice

**Legal Requirements**

This Institution commits to apply its ethical standards to all Human Research regardless of funding.

All Human Research must undergo review by one of the institutionally designated IRBs. Activities that do not meet the definition of Human Research do not require review and approval by one of the Institution’s IRBs and do not need to be submitted to one of the Institution’s IRBs unless there is a question regarding whether the activity is Human Research.

When this Institution is engaged in DHHS Human Research that is conducted, funded, or otherwise subject to regulations by a federal department or agency who is a signatory of the Common Rule, the Institution commits to apply the regulations of that agency relevant to the protection of Human Subjects.

When this Institution is engaged in FDA Human Research, this Institution commits to apply the FDA regulations relevant to the protection of Human Subjects.

Any questions about whether an activity meets the regulatory definitions of Human Research should be referred to the Office of Human Subject Protections (OHSP) who will provide a determination.
Other Requirements

When reviewing research that involves community-based research, the IRB obtains consultation or training.

All policies and procedures are applied identically to all research regardless of whether the research is conducted domestically or in another country, including:

- Confirming the qualifications of investigators for conducting the research
- Conducting initial review, continuing review, and review of modifications to previously approved research
- Post-approval monitoring
- Handling of complaints, non-compliance, and unanticipated problems involving risks to subjects or others
- Consent process and other language issues
- Ensuring all necessary approvals are met
- Coordination and communication with local IRBs

For clinical trials, this Institution commits to apply the “International Conference on Harmonisation – Good Clinical Practice E6” (ICH-GCP) when required by industry sponsors.

This Institution prohibits payments to professionals in exchange for referrals of potential subjects (“finder’s fees”) and payments designed to accelerate recruitment that were tied to the rate or timing of enrollment (“bonus payments.”)

This Institution utilizes the IRB to review and approve the use of a Humanitarian Use Device (HUD) before it can be used at a facility for clinical care (with the exception of emergency use).

When Human Research is conducted or funded by the Department of Defense (DOD), this Institution commits to apply the Department of Defense (DOD) Directive 3216.02, which includes the requirement to apply 45 CFR §46 Subparts B, C, and D. This Institution will comply with the terms of the DFARS clause or comparable language used in the agreement with the Department of Defense (DOD) Component supporting the research involving human subjects.

When Human Research is conducted or funded by the Department of Education (ED), this Institution commits to applying 34 CFR §97 Subpart D (equivalent to 45 CFR §46 Subpart D), 34 CFR §98.3, 34 CFR §98.4, 34 CFR §356.3, and 34 CFR §99.

When Human Research is subject to the European Union General Data Protection Regulations (GDPR), this Institution coordinates with legal counsel to ensure that the research activities

3 Quick applicability table for DHHS Subparts:

<table>
<thead>
<tr>
<th></th>
<th>DHHS</th>
<th>DOD</th>
<th>ED</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subpart B</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Subpart C</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Subpart D</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>
conform to broader institutional policies related to GDPR, where applicable, as well as legal counsel’s interpretation of study-specific GDPR requirements.

**Sponsored Human Research**

For both sponsored and non-sponsored Human Research this Institution abides by its ethical principles, regulatory requirements and its policies and procedures.

**Scope of Human Research Protection Program**

The categories of Human Research overseen include:

- International research
- Research conducted or funded by the Department of Defense (DOD)
- Research conducted or funded by the Department of Education (ED)
- Federally funded research
- FDA-regulated research.
- Research involving drugs that require an IND.
- Research involving devices that require an abbreviated IDE.
- Research involving devices that require an IDE issued by FDA.
- Investigator held abbreviated IDE.
- Investigator (Institution) held IND or IDE.
- Research involving pregnant women as subjects.
- Research involving non-viable neonates.
- Research involving neonates of uncertain viability.
- Research involving children as subjects.
- Research involving children, pregnant women, fetuses, or neonates that is not otherwise approvable without approvable of an agency secretary or director.
- Research involving a waiver of consent for planned emergency research.
- Emergency use of a test article in a life threatening situation.
- Activities involving humanitarian use devices.
- Research using the short form of consent documentation.
- Research that includes processing or holding personal data of subjects residing in the European Union.

The categories of Human Research not overseen include:

- Classified Research (Classified research is secret research to which access is restricted by law to a particular hierarchical class of people. A security clearance is required to review classified research.)
- Research conducted or funded by the Veteran Administration (VA)
- Research conducted or funded by the Department of Justice (DOJ)
- Research conducted or funded by the Department of Energy (DOE)
- Research conducted, funded, or subject to oversight by the Environmental Protection Agency (EPA)
• Research involving fetuses.
• Research involving in vitro fertilization.
• Research that plans to or is likely to involve prisoners as subjects.

Human Research Protection Program Policies and Procedures
Policies and procedures for the Human Research Protection Program are available in the ePRTCL IRB Library

Human Research Protection Program Components

Institutional Official/Organizational Official (IO/OO)
The Vice President for Clinical Research is designated as the IO/OO.
The IO/OO has the authority to take the following actions or delegate these authorities to a designee:
• Create the Human Research Protection Program budget.
• Allocate resources within the Human Research Protection Program budget.
• Appoint and remove IRB members and IRB chairs.
• Hire and fire research review staff.
• Determine what IRBs the Institution will rely upon.
• Approve and rescind authorization agreements for IRBs.
• Place limitations or conditions on an investigator’s or research staff’s privilege to conduct Human Research.
• Create policies and procedures related to the Human Research Protection Program that are binding on the Institution.
• Suspend or terminate research approved by one of the Institution’s IRBs.
• Disapprove research approved by one of the Institution’s IRBs.
• Establish a contingency plan for transferring oversight of one or more studies to another institution or IRB in the event the IRB is unable to continue oversight of the study (e.g., the IRB closes, suffers loss due to fire, natural disaster).

The IO/OO has the responsibility to:
• Oversee the review and conduct of Human Research under the jurisdiction of the Human Research Protection Program.
• Periodically review this plan to assess whether it is providing the desired results and recommend amendments as needed.
• Establish policies and procedures designed to increase the likelihood that Human Research will be conducted in accordance with ethical and legal requirement.
• Institute regular, effective, educational and training programs for all individuals involved with the Human Research Protection Program.
• Ensure that the research review process is independent and free of coercion or undue influence, and ensure that officials of the Institution cannot approve research that has not been approved by one of the IRBs designated by the Institution.
• Ensure that the IRB Chair(s) and members have direct access to the IO for appeal if they experience undue influence or if they have concerns about the function of the IRB.
• Implement a process to receive and act on complaints and allegations regarding the Human Research Protection Program.
• Follow-up on findings of serious or continuing non-compliance of IRB staff and IRB members.
• Implement an auditing program to monitor compliance and improve compliance in identified problem areas.
• Investigate and remediate identified systemic problem areas, and where necessary removal of individuals from involvement in the Human Research protection program.
• Ensure that the Human Research Protection Program has sufficient resources, including IRBs appropriate for the volume and types of Human Research to be reviewed, so that reviews are accomplished in a thorough and timely manner.
• Review and sign federal assurances (FWA) and addenda.
• Fulfill educational requirements mandated by OHRP.

All members of the Institution

All individuals within the Institution have the responsibility to:
• Be aware of the definition of Human Research.
• Consult the IRB when there is uncertainty about whether an activity is Human Research.
• Not conduct Human Research or allow Human Research to be conducted without review and approval by an IRB designated by the IO/OO.
• Report allegations of undue influence regarding the oversight of the Human Research Protection Program or concerns about the Human Research Protection Program to the IO/OO.
• Report allegations or finding of non-compliance with the requirements of the Human Research Protection Program to the IRB.

Individuals who are responsible for business development are prohibited from carrying out day-to-day operations of the review process.

IRBs

The list of IRBs designated by the IO/OO to be the IRBs relied upon by the Human Research Protection Program and the scope of review of these IRBs is listed in the IRB rosters available from the OHSP. IRB members and IRB staff have the responsibility to follow Human Research Protection Program policies and procedures that apply to IRB members and staff.

Relying on an External IRB

This Institution may rely upon IRBs of another institution or organization provided one of the following is true:
• The IRBs are part of an AAHRPP accredited institution or organization.
• The IRBs are not part of an AAHRPP accredited institution or organization, but where reasonable steps have been taken to ensure that subjects are adequately protected. For example, for research that is no greater than Minimal Risk, there may be an assurance that the IRBs will adhere to applicable ethical standards and regulations. For research that is greater than Minimal Risk, the institutions may agree on more extensive oversight.
• The IRBs are part of an established reliance network (e.g. Smart IRB) that has established contractual and SOP-level procedures to clarify the roles and responsibilities associated with IRB reliance and to establish mechanisms to ensure quality and consistency in the review process among institutions.
• The sIRB has been pre-determined by study sponsor or grant or established by prior arrangement.
• This Institution’s investigator is a collaborator on Human Research that is primarily conducted at another institution or organization and the investigator’s role does not include interaction or intervention with subjects.
• The Institution is engaged in the Human Research solely because it is receiving federal funds. (Employees and agents of the institution do not interact or intervene with subjects, gather or possess private identifiable information about subjects, nor obtain the consent of subjects.)

Reliance on an external IRB requires an Authorization Agreement and an active Institutional Profile, as well as a local review for compliance with local policies of the Institution. When Human Research carried out at this Institution or by its agents is reviewed by an IRB at another institution or organization, this HRPP will follow established policies and procedures that specify which studies are eligible for reliance, how reliance is determined, and will provide information to researchers about reliance criteria and the process for seeking IRB reliance.

The IRBs relied upon by this Institution have the authority to:
• Approve, require modifications to secure approval, and disapprove all Human Research overseen and conducted by the Institution. All Human Research must be approved by one of the IRBs designated by the IO/OO. Officials of this Institution may not approve Human Research that has not been approved by one of the Institution’s IRBs.
• Suspend or terminate approval of Human Research not being conducted in accordance with an IRBs’ requirements or that has been associated with unexpected serious harm to subjects.
• Observe, or have a third party observe, the consent process and the conduct of the Human Research.
• Determine whether an activity is Human Research.
• Evaluate financial interests of investigators and research staff and have the final authority to decide whether the financial interest and management plan, if any, allow the Human Research to be approved.
• Serve as the Privacy Board, as applicable, to fulfill the requirements of the HIPAA Privacy Rule for use or disclosure of protected health information for research purposes.

This institution will comply with the determinations of the reviewing IRB, follow reporting and conflict of interest disclosure requirements as specified in the authorization agreement, conduct monitoring, identify an appropriate contact person, ensure researchers have appropriate qualifications and provide local context information (and any updates) to the reviewing IRB.

**Serving as the IRB of Record**

When this institution provides IRB review for other institutions, this HRPP will follow established policies and procedures to ensure that the composition of the IRB is appropriate to review the research and will comply with applicable laws of the relying site. This includes ensuring the IRB is appropriately constituted, members are appropriately qualified, members will not participate in the review of research in which they have a conflict of interest; and that the IRB separates business functions from ethical review.

The IRB will review the research in accordance with established policies and procedures to determine that research is ethically justifiable, according to all applicable laws, including initial review, continuing review, review of modifications to previously approved research and unanticipated problems involving risks to subjects or others. The IRB will also have the ability to suspend or terminate IRB approval; as well as have the final authority to decide whether researcher or research staff conflict of interest and its management, if any, allows the research to be approved and request audits of research reviewed.

The IRB will notify the researcher (and organization) of its decisions, make relevant IRB policies and records available to the relying institution or organization and specify an IRB contact for communication.

**Investigators and Research Staff**

Investigators and research staff have the responsibility to:

• Follow the Human Research Protection Program requirements described in HRP-103 - INVESTIGATOR MANUAL.
• Comply with all determinations and additional requirements of the IRB, the IRB chair, and the IO/OO.

**Legal Counsel**

Legal Counsel has the responsibility to:
• Provide advice upon request to the IO/OO, IRB, and other individuals involved with the Human Research Protection Program.
• Determine whether someone is acting as an agent of the Institution.
• Determine who meets the definition of “legally authorized representative” and “children” when Human Research is conducted in jurisdictions not covered by policies and procedures.
• Resolve conflicts among applicable laws.
• Determine whether any Human Research involving personal data about individuals located in (but not necessarily citizens of) European Union member states, Norway, Iceland, Liechtenstein, and Switzerland conforms with EU General Data Protection Regulations (GDPR).

**Division Heads//Department Chairs**

Division Heads, Deputy Division Heads and Department Chairs have the responsibility to:

• Oversee the review and conduct of Human Research in their department.
• Forward complaints and allegations regarding the Human Research Protection Program to the IO/OO.
• Ensure that each Human Research study conducted in their department has adequate resources.

**Research Compliance Program**

The goal of the research compliance program is to ensure that all research (including clinical, behavioral, and translational research) is conducted according to the highest ethical standards and in compliance with all applicable laws, rules, guidelines, and institutional policies. In addition, MD Anderson’s Senior Legal Officer & Director, Research Compliance, provides institutional legal and regulatory counsel, and provides legal research and analysis for complex research compliance-related legal issues, including issues regarding human subjects research and participant protection, to MD Anderson, its researchers, its IRBs, and the Vice President for Clinical Research.

**Scientific Review Committee (SRC)**

The SRCs are officially constituted committees of The University of Texas MD Anderson Cancer Center that report to the Vice President for Clinical Research. MD Anderson’s SRCs evaluate the scientific content and prioritization of all clinical protocols, including investigator-initiated, pharmaceutical and biotechnology company-sponsored; multi-institutional; and other clinical investigation protocols deemed as high-risk.

**Data Safety Monitoring (DSM)**

The DSM committees report to the President, or designee, as the on-campus representative of The University of Texas Board of Regents. This board consists of clinical faculty and biostatisticians from both MD Andersons as well as clinical faculty from other educational
institutions. The DSM committees are charged with overseeing the data and patient safety issues for all MD Anderson’s Investigator Initiated Trials.

**Institutional Conflict of Interest Committee (ICOI Committee)**
MD Anderson’s ICOI Committee serves as an advisory committee to The University of Texas System and is responsible for reviewing MD Anderson’s Significant Financial Interests and MD Anderson’s Institutional Decision Makers’ Financial Interests to determine if those interests constitute an Institutional Conflict of Interest (ICOI), and for addressing identified ICOIs through reduction, management, or elimination of such ICOIs.

**Conflict of Interest Committee (COIC)**
MD Anderson’s COIC reviews financial relationship disclosures from all investigators, faculty, trainees, and institutional decision makers and determines if such relationships constitute an individual conflict of interest, and requires such individuals to reduce, manage, or eliminate the conflict of interest. The IRBs have the authority to determine additional measures as it deems necessary for the protection of human subjects.

**Environmental Health and Safety (EH&S)**
The MD Anderson EH&S program ensures low impact of hazardous pollutants to air, water, and land through compliance with federal, state, and local environmental regulations and operations to reduce pollution and promote environmental stewardship. EH&S works with investigators to promote a safe laboratory environment. Under EH&S, Laboratory Safety, identifies the basic principles employees should apply to protect themselves against all work hazards, including those related to environmental protection, laboratory safety, radiation safety, business continuity, emergency management, food safety, product recalls, operations and facilitates management, zone inspection, fire and life safety, construction safety, and occupational health safety.

**Radiation Safety Committee (RSC)**
MD Anderson’s Radiation Safety Committee (RSC) is qualified through the experience and expertise of its members to oversee the institution’s radiation program, facilities and procedures. The President of MD Anderson appoints the Members, Chair, and Vice-Chair of the RSC. The President delegates authority to the RSC to ensure the safe handling of radioactive material, radioactive sources, and radiation-producing machines. The committee reports to the President of MD Anderson.

**Internal Audit**
MD Anderson’s Internal Audit department (IA) is established under the authority of, and in accordance with the Texas Internal Auditing Act and The University of Texas System Board of Regents. IA, with strict accountability for confidentiality and safeguarding records and information, is authorized full, free, and unrestricted access to any and all of MD Anderson’s
records, physical properties, and personnel pertinent to carrying out any engagement. The scope of internal auditing carried out by IA includes MD Anderson’s HRPP.

Office of Sponsored Programs (OSP)
The Office of Sponsored Programs has the responsibility to review contracts and funding agreements for compliance with Human Research Protection Program policies and procedures.

Department of Investigational Pharmacy Services (IPS)
The Department of Investigational Pharmacy Services (IPS) is responsible for the administrative management of all investigational drugs used at MD Anderson. Specific operational responsibilities of this office include but are not limited to drug acquisition, inventory control and investigational drug accountability in compliance with state and federal regulations. An equally important function is the provision of drug information of these agents and protocols for health care professionals within the institution. The IPS serves as the liaison between researchers, IND sponsors, and the Division of Pharmacy in addition to ensuring pharmacy compliance with protocol requirements.

The Quality Improvement Assessment Board (QIAB)
The Quality Improvement Assessment Board (QIAB) is established by Institutional Policy, Quality Assessment Improvement Board Policy (ADM1080) and reviews all MDACC Quality Improvement (QI) projects to: assure patient safety; optimize the potential benefits being sought; and discern which projects may be more appropriately designed or categorized as research studies requiring Institutional Review Board (IRB) oversight.

Education and Training
The Office of Protocol Support & Management works with MD Anderson departments and other institutions to offer comprehensive education to the MD Anderson research community. IRB members, IRB staff, and others involved in the review of Human Research, including the IO/OO, must complete initial and continuing training.

Investigators and research staff must complete the initial and continuing training described in HRP-103 - INVESTIGATOR MANUAL.

Questions and Additional Information for the IRB
The OHSP wants your questions, information, and feedback.

Contact and location information for the OHSP is:
Office of Human Subjects Protection
7007 Bertner Ave., Unit 1637
Houston, TX 77030
Email: IRB_Help@mdanderson.org
(713) 792-6477
**Reporting and Management of Concerns**

Questions, concerns, complaints, allegations of undue influence, allegations or findings of non-compliance, or input regarding the Human Research Protection Program may be reported orally or in writing. Employees are permitted to report concerns on an anonymous basis. Concerns may be reported to the IRB Chair, the OHSP, Organizational Official, Legal Counsel, Deans, or Department Chairs.

The IRB has the responsibility to investigate allegations and findings of non-compliance and take corrective actions as needed. The IO/OO has the responsibility to investigate all other reports and take corrective actions as needed.

Employees who report in good faith possible compliance issues should not be subjected to retaliation or harassment as a result of the reporting. Concerns about possible retaliation should be immediately reported to the IO/OO or designee.

To make such reports, contact the IO/OO:

Jennifer Litton, MD  
Vice President, Clinical Research  
VP Clinical Research Administration  
1515 Holcombe Blvd. Unit 1634  
Houston, TX 77030-3907  
Email: IO-MDA@mdanderson.org  
(713) 794-7139

**Monitoring and Auditing**

In order to monitor and ensure compliance, internal or external auditors who have expertise in federal and state statutes, regulations and institutional requirements will conduct periodic audits. Audits will focus on areas of concern that have been identified by any entity, i.e., federal, state or institutional. Random audits may also be conducted.

**Disciplinary Actions**

The IO/OO may place limitations or conditions on an investigator’s or research staff’s privilege to conduct Human Research whenever in the opinion of the IO/OO such actions are required to maintain the Human Research Protection Program.

**Approval and Revisions to the Plan**

This Human Research Protection Program Plan is to be approved by the IO/OO. This plan is intended to be flexible and readily adaptable to changes in regulatory requirements. The IO/OO has the responsibility to review this plan to assess whether it is providing the desired results. The IO/OO has the authority to amend this plan as deemed necessary.
Approved:

Jennifer Litton, MD
Vice President for Clinical Research
December 6, 2021